TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12584671

Group type: EXPERIMENTAL
Intervention: Omapatrilat 40 mg
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Omapatrilat 20 mg
Number of subjects: 723

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 723
Study: 10637684

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment (methylphenidate or placebo)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Nonpharmacological treatment (parent groups: training or support)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pharmacological and nonpharmacological treatments
Number of subjects: 81
Study: 8546281

Group type: EXPERIMENTAL
Intervention: External high frequency oscillation at 1-5 Hz
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: External high frequency oscillation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation
Number of subjects: 20
Study: 1975189

Group type: EXPERIMENTAL
Intervention: Esmolol 100 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Esmolol 200 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Esmolol (100 mg and 200 mg)
Number of subjects: 32
Study: 7270984

Group type: EXPERIMENTAL
Intervention: Albuterol syrup
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31472678

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation + gluten-free diet (PRO-GFD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo supplementation + gluten-free diet (PLA-GFD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation + gluten-containing diet (PRO-GD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo supplementation + gluten-containing diet (PLA-GD)
Number of subjects: 120
Study: 28374907

Group type: EXPERIMENTAL
Intervention: 2% (v/v) glycerine added to a reduced volume of soaking water
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group (current skincare regimen)
Number of subjects: 193
Study: 26708707

Group type: EXPERIMENTAL
Intervention: Dutch community-based alcohol intervention
Number of subjects: 5700

Group type: COMPARATOR
Intervention: Reference region (control)
Number of subjects: 5700
Study: 24608079

Group type: EXPERIMENTAL
Intervention: Higher dose intravenous methotrexate (MTX) 2.5 g/m
Number of subjects: 784

Group type: COMPARATOR
Intervention: Standard dose intravenous methotrexate (MTX) 1 g/m
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: High-dose cytosine arabinoside/asparaginase
Number of subjects: 784

Group type: COMPARATOR
Intervention: Cytosine arabinoside/teniposide
Number of subjects: 784
Study: 23012385

Group type: EXPERIMENTAL
Intervention: 500 mg intravenous doripenem
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1000 mg intravenous doripenem
Number of subjects: 12
Study: 19281588

Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 164
Study: 17804673

Group type: EXPERIMENTAL
Intervention: Perindopril-based blood pressure-lowering therapy
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study: 15141263

Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg per rectum every 4 hours
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo per rectum every 4 hours
Number of subjects: 42
Study: 12667363

Group type: COMPARATOR
Intervention: Calcium carbonate (Ca) 400 mg/d + vitamin D 200 IU/D (Control group)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: E(2)V 1.0 mg/d + MPA 2 mg/d + Ca 400 mg/d (Treatment group 1)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: E(2)V 1.0 mg/d + MPA 2 mg/d + Ca 400 mg/d + vitamin D 200 IU/d (Treatment group 2)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: E(2)V 1.5 mg/d + MPA 2 mg/d + Ca 400 mg/d + vitamin D 200 IU/d (Treatment group 3)
Number of subjects: 92
Study: 10604697

Group type: EXPERIMENTAL
Intervention: Antegrade percutaneous approach
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Retrograde hot-wire balloon incision
Number of subjects: 60
Study: 7818118

Group type: EXPERIMENTAL
Intervention: 3 mL of 1.5% lidocaine with epinephrine (1:200,000) IV
Number of subjects: 30

Group type: COMPARATOR
Intervention: 3 mL of normal saline IV
Number of subjects: 30
Study: 1703451

Group type: EXPERIMENTAL
Intervention: Carboplatin 300 mg/m2 and fluoro‐uracil 1000 mg/m2/d administered in continuous IV infusion for 96 h every 4 weeks (group 1)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Carboplatin 350 mg/m2 and fluoro‐uracil administered at the same dose every 3 weeks (group II)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both groups (combined therapy with carboplatin and fluoro‐uracil)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Group II
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 113
Study: 380347

Group type: EXPERIMENTAL
Intervention: cefamandole
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: cephalothin
Number of subjects: 120

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study: 31812686

Group type: EXPERIMENTAL
Intervention: Vaginal estradiol
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Moisturizer
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Vulvovaginal symptom severity
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Depression symptoms (PHQ-8)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Recent sexual activity
Number of subjects: 301
Study: 31398376

Group type: EXPERIMENTAL
Intervention: 25% Calorie Restriction (CR)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Ad libitum (AL)
Number of subjects: 218
Study: 28446631

Group type: EXPERIMENTAL
Intervention: Balanced protein‐energy supplementation of 500 mL milk/d plus a 10‐μg vitamin B‐12 tablet/d (M+B‐12 group)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Milk (500 mL/d) plus a placebo tablet (M+P group)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo tablet alone (P group)
Number of subjects: 93
Study: 25848883

Group type: EXPERIMENTAL
Intervention: HD bronchoscopy with surface- and tone enhancement technique (i-scan2)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Dual mode autofluorescence videobronchoscopy (AFB)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: AFB
Number of subjects: 29

Group type: COMPARATOR
Intervention: White light bronchoscopy (WLB) and HD bronchoscopy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All modalities
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: HD bronchoscopy with i-scan
Number of subjects: 29
Study: 23996419

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ethanol with lorazepam
Number of subjects: 57
Study: 21181130

Group type: EXPERIMENTAL
Intervention: Oral cortisol (30 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20009074

Group type: EXPERIMENTAL
Intervention: Remote magnetic catheter navigation (RMN)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional manual catheter ablation
Number of subjects: 90
Study: 17978289

Group type: EXPERIMENTAL
Intervention: S-1 (80 mg/m²/day for 4 weeks followed by 2 weeks off, for 1 year)
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 1059
Study: 14604720

Group type: EXPERIMENTAL
Intervention: Sharp-edged Sensar OptiEdge AR40e IOL (Allergan Surgical)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Round-edged Sensar AR40 IOL
Number of subjects: 52
Study: 10773509

Group type: EXPERIMENTAL
Intervention: Clonidine (3 micrograms/kg, 15 min before induction)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8642820

Group type: EXPERIMENTAL
Intervention: Ultrasonic aspirator at 60% power output
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ultrasonic aspirator at 80% power output
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ultrasonic aspirator at 100% power output
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ultrasonic aspirator in 100% CAVI‐Pulse mode 1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ultrasonic aspirator in 100% CAVI‐Pulse mode 3
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional electrocautery
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All settings of electrocautery with an ultrasonic aspirator
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acetylcholine and sodium nitroprusside
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 6
Study: 1632393

Group type: EXPERIMENTAL
Intervention: Simultaneous biphasic shocks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Simultaneous monophasic shocks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sequential monophasic shocks
Number of subjects: 33
Study: 6084754

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg b.i.d. for 10 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 27
Study: 3762240

Group type: EXPERIMENTAL
Intervention: Physician/nurse talk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reminder postcard
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reminder phone call
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 29383065

Group type: EXPERIMENTAL
Intervention: SMART Goal Enhanced Debriefing
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard Debriefing
Number of subjects: 80
Study: 26654244

Group type: EXPERIMENTAL
Intervention: Single 300 ml dose of anthocyanin-rich cherry juice
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 3 x 100 ml doses of anthocyanin-rich cherry juice
Number of subjects: 13
Study: 23845721

Group type: EXPERIMENTAL
Intervention: Endobronchial valve therapy (EBV)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Conservative therapy (control)
Number of subjects: 416
Study: 22594100

Group type: EXPERIMENTAL
Intervention: Needling sensation acupuncture
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Shallow acupuncture
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 29

Group type: COMPARATOR
Intervention: Non-acupoint acupuncture
Number of subjects: 29

Group type: COMPARATOR
Intervention: Deep acupuncture
Number of subjects: 29
Study: 20820148

Group type: EXPERIMENTAL
Intervention: Fenoldopam 0.05-mcg/kg/min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no fenoldopam)
Number of subjects: 40
Study: 19127796

Group type: EXPERIMENTAL
Intervention: Short-term amoxicillin-clavulanic acid
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Long-term penicillin
Number of subjects: 122

Group type: COMPARATOR
Intervention: Short-term penicillin
Number of subjects: 122

Group type: COMPARATOR
Intervention: Long-term amoxicillin-clavulanic acid
Number of subjects: 122
Study: 17085378

Group type: EXPERIMENTAL
Intervention: Sequential oral and transdermal estradiol regimen (2 mg oral micronized 17beta‐estradiol/day or 1.5 mg 17beta‐estradiol gel/day) combined with oral dydrogesterone (10 mg/day, 12 days/month) for 1 year
Number of subjects: 15
Study: 12800871

Group type: EXPERIMENTAL
Intervention: Homogenized cow's milk
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Unhomogenized cow's milk
Number of subjects: 44
Study: 10805047

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation training session
Number of subjects: 7

Group type: COMPARATOR
Intervention: Non-exercise control day
Number of subjects: 7
Study: 8729096

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1796408

Group type: EXPERIMENTAL
Intervention: Heparin intravenously 30,000-40,000 U daily
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 6823433

Group type: EXPERIMENTAL
Intervention: Diet free from cow's milk
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cow's milk whey protein
Number of subjects: 66
Study: 30613964

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT) alone
Number of subjects: 480
Study: 28622081

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 18
Study: 27315239

Group type: COMPARATOR
Intervention: Yoga program for 60 minutes once a week for 12 weeks.
Number of subjects: 40
Study: 24490842

Group type: EXPERIMENTAL
Intervention: 15‐minute script via an iPod leading through visual imagery (cognitive relaxation) or deep breathing exercises (somatic relaxation)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group listened to 15 minutes of ambient nature sounds
Number of subjects: 97
Study: 21406956

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation intervention for 2 months, weekly group sessions.
Number of subjects: 114
Study: 20408391

Group type: EXPERIMENTAL
Intervention: Modified NIDA Standard Intervention (SI)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: SI + Well Woman Exam (SI+WWE)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: SI + Well Woman Exam + 4 Educational Sessions (SI+WWE+4ES)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Standard Intervention (SI)
Number of subjects: 501
Study: 17684658

Group type: EXPERIMENTAL
Intervention: BTE hearing aids with open molds
Number of subjects: 50

Group type: COMPARATOR
Intervention: BTE hearing aids with pressure vent molds
Number of subjects: 50
Study: 16271337

Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg 3 times daily)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 12600812

Group type: EXPERIMENTAL
Intervention: Tiagabine (add-on therapy)
Number of subjects: 574
Study: 10368798

Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg implant four weekly + placebo tablets daily (Group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg implant four weekly + estradiol valerate 2 mg daily with norethisterone 5 mg from days 21-28 of a 28-day cycle (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo implant four weekly + placebo tablets daily (Group A)
Number of subjects: 60
Study: 8897354

Group type: EXPERIMENTAL
Intervention: 5,6 benzo‐[alpha]‐pyrone (coumarin 400 mg/day) for six months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for six months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Heat therapy (microwave) plus compression garments for six months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Benzopyrones for 12 months plus heat treatment for six months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Heat therapy plus either placebo or benzopyrone
Number of subjects: 60
Study: 1509748

Group type: EXPERIMENTAL
Intervention: CEDIA assays
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluorescence polarization immunoassay
Number of subjects: 0

Group type: COMPARATOR
Intervention: HPLC
Number of subjects: 0
Study: 6711782

Group type: EXPERIMENTAL
Intervention: 0.4 mg buprenorphine pre‐emptively for postoperative pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine or placebo
Number of subjects: 0
Study: 30662387

Group type: EXPERIMENTAL
Intervention: Fentanyl combined with midazolam
Number of subjects: 44

Group type: COMPARATOR
Intervention: Midazolam alone (control group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 28993346

Group type: EXPERIMENTAL
Intervention: Immediate active treatment with intravenous abatacept
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed treatment arm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 20
Study: 27260839

Group type: EXPERIMENTAL
Intervention: Talactoferrin (TLf) 150 mg/kg every 12 hours for 28 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Talactoferrin (TLf)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Talactoferrin (TLf) and Placebo
Number of subjects: 120
Study: 24929798

Group type: EXPERIMENTAL
Intervention: Moderate or intense supervised exercise training thrice-weekly for 12 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (DM without neuropathy)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (DM-PN with neuropathy)
Number of subjects: 37
Study: 22532269

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20393508

Group type: EXPERIMENTAL
Intervention: HGF plasmid (beperminogene perplasmid, Collategene) injected intramuscularly on days 0 and 28
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo injected intramuscularly on days 0 and 28
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: HGF plasmid (beperminogene perplasmid, Collategene) injected intramuscularly
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo injected intramuscularly
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: HGF plasmid (beperminogene perplasmid, Collategene)
Number of subjects: 44
Study: 18780502

Group type: EXPERIMENTAL
Intervention: Combined in-office cold light bleaching and night-guard vital bleaching (NGVB) system
Number of subjects: 90

Group type: COMPARATOR
Intervention: In-office cold light bleaching
Number of subjects: 90

Group type: COMPARATOR
Intervention: Night-guard vital bleaching (NGVB)
Number of subjects: 90
Study: 15824494

Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 54

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 54
Study: 12424329

Group type: EXPERIMENTAL
Intervention: Lycopene supplementation (30 mg of lycopene from tomato oleoresin extract)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No supplementation (control group)
Number of subjects: 26
Study: 10090434

Group type: EXPERIMENTAL
Intervention: 5-day grepafloxacin 400 mg once daily
Number of subjects: 389

Group type: COMPARATOR
Intervention: 10-day grepafloxacin 400 mg once daily
Number of subjects: 389
Study: 7788193

Group type: EXPERIMENTAL
Intervention: Additional warming
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 14
Study: 2190405

Group type: EXPERIMENTAL
Intervention: Intravesical Bacillus Calmette-Guérin (BCG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 85162

Group type: EXPERIMENTAL
Intervention: Domperidone (60 mg daily) with bromocriptine (mean dose 148 mg daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo with bromocriptine (average daily dose 92 mg)
Number of subjects: 17
Study: 31642699

Group type: EXPERIMENTAL
Intervention: Ferritin measured at birth (umbilical cord sample), 48-72 hours, 4 months and 12 months
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Ferritin measured at 12 months
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Ferritin measured at 0-3 days of age
Number of subjects: 456
Study: 26873098

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BTJ) 250 ml
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole beetroot (BF) 300 g
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 10
Study: 25531167

Group type: EXPERIMENTAL
Intervention: Just-in-time (JIT) training before CPA
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Real-time visual feedback (VisF) during CPA
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Combination of JIT training and real-time VisF
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group (no JIT training and no VisF)
Number of subjects: 324
Study: 24021679

Group type: EXPERIMENTAL
Intervention: Intracerebral hemorrhage cases
Number of subjects: 2506

Group type: COMPARATOR
Intervention: Controls matched by age, race, ethnicity, sex, and metropolitan region
Number of subjects: 2506

Group type: EXPERIMENTAL
Intervention: Cases with imaging submitted
Number of subjects: 2506

Group type: EXPERIMENTAL
Intervention: Cases with MRI evaluation
Number of subjects: 2506
Study: 21946357

Group type: EXPERIMENTAL
Intervention: Microalbuminuria group (n=96)
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Microalbuminuria group (n=96) in diabetic patients
Number of subjects: 920
Study: 19673331

Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SMI) 0.6 mL/kg in 250 mL physiological saline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group received 250 mL physiological saline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SMI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 16840747

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) administered by intravenous infusion at Weeks 0, 2, and 6
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 14699431

Group type: EXPERIMENTAL
Intervention: Melancholic depression
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Melancholic subjects
Number of subjects: 38
Study: 11273875

Group type: EXPERIMENTAL
Intervention: Melatonin (MEL) 0.3 mg/kg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intravenous iron (100 mg of Fe saccharate)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Recombinant human erythropoietin (rHuEPO 4,000 U)
Number of subjects: 9
Study: 9237085

Group type: EXPERIMENTAL
Intervention: Talking privately about stressful events (disclosure group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Talking about trivial topics (control group)
Number of subjects: 72
Study: 8055403

Group type: EXPERIMENTAL
Intervention: Low income (less than $10,000)
Number of subjects: 2503

Group type: EXPERIMENTAL
Intervention: Noneconomic factors (low maternal education and family dysfunction)
Number of subjects: 2503

Group type: COMPARATOR
Intervention: Control group (children with income above $10,000)
Number of subjects: 2503
Study: 3057832

Group type: EXPERIMENTAL
Intervention: CSF-HU (P-100) administered at 2 vials/day (8 X 10(6)U of P-100) by intravenous drip infusion for 7 days starting from the 5th day after chemotherapy initiation.
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo (inactive) administered in the same manner as P-100.
Number of subjects: 261